Board of Directors
Chairman; Partner, Third Rock Ventures
Third Rock Ventures partner Cary Pfeffer is chairman of Neon Therapeutics’ board of directors. He joined Third Rock Ventures at its inception in 2007 and has more than 20 years of business development and transaction experience, along with a broad array of biotech product development experience.
Entrepreneur-In-Residence, Third Rock Ventures
Since 2010, Bob Kamen has served as an entrepreneur-in-residence at Third Rock Ventures. Bob focuses on the formation and development of biologics companies that develop life-changing therapies for patients. Bob brings more than 30 years of leadership experience in the pharmaceutical and
Founding Director, Broad Institute
Eric Lander is one of the driving forces behind today’s revolution in genomics and currently serves as the founding director of the Broad Institute. Eric is also a professor of biology at Massachusetts Institute of Technology and professor of systems biology at Harvard Medical School.
Chief Executive Officer, Neon Therapeutics
Neon Therapeutics’ chief executive officer, Hugh O’Dowd, joined the company in 2016, bringing more than 20 years of expertise in pharmaceutical leadership and moving important oncology therapies from clinical development through commercialization. Hugh joined Neon Therapeutics from Novartis
Clinical Professor of Medicine, University of California San Francisco
Stephen Sherwin currently divides his time between advisory work in the life science industry and patient care and teaching in his specialty of medical oncology. He is a clinical professor of medicine at the University of California, San Francisco and a volunteer attending physician in
Partner, Third Rock Ventures
Bob Tepper is a co-founder of Third Rock Ventures and a distinguished scientist with more than 30 years of experience building and operating leading R&D organizations in the biotech industry. Bob focuses on the formation, development and scientific strategy of Third Rock’s portfolio companies, as
Chairman & CEO, Gamida Cell
Julian Adams is a renowned scientist known for his success developing high-impact therapies for cancer and HIV. Julian played a pivotal role in the development of multiple products to reach the market, including Viramune® (nevirapine) for HIV, and Velcade® (bortezomib), a proteasome inhibitor that
Former Novartis executive